


About Vycellix™, Inc.

Visit us on the web at: www.Vycellix.com

Vycellix, Inc. is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and Natural Killer (NK) cell-based cancer therapies.

The Company's platforms include:

- **VY-UC** to generate immune-privileged universal cells without altering the components that control self-recognition (HLA), obviating the need for immune-suppressive drugs in contexts of allogeneic cell therapies, hence redefining “off-the-shelf” treatment strategies
- **VY-OZ** to significantly enhance gene transduction rates and modify cells for immunotherapies and beyond
- **VY-M** to accelerate expansion of cells, including immune cells, resulting in shorter “vein-to-vein” delivery time of new cell therapies to patients
- **VY-X** to amplify serial tumor-killing capacity of T cells and NK cells via the selective upregulation of cytotoxic mechanisms



Collaborating with Scientists at Karolinska Institutet

The Company's platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden. Vycellix is a collaborative partner in “NextGenNK”, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovation agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.



Pipeline Spotlight: VY-UC

Redefining “Off-the-Shelf” Cell-based Treatment Strategies

Successfully transplanting cells and tissues without the risk of immune rejection or the need for immunosuppressive drugs is the “Holy Grail” of donor cell-based medicine. Vycellix’s novel **VY-UC** platform represents a highly-differentiated approach to transform donor cells into immune privileged cells with key advantages that include:

- Abrogating recognition by cellular immune response
- Eliminating need to modulate HLA Class I and/or II expression
- Not compromising cellular function
- Allowing for utilization in transient or permanent settings
- Redefining how allogeneic therapies can be utilized, obviating the need for immunosuppressive agents

VY-UC: Market Opportunity

Transforming Donor-based Medicines:

- T Cell & NK Cell-based Cancer Immunotherapy
- Organ & Tissue Transplantation
- Platelets & Red Blood Cells for Transfusions
- Insulin Producing Cells for Diabetes
- Retinal Cells for Ocular Disease
- Cardiac Progenitors for Heart Disease
- Regulatory T Cells for Autoimmune Disease
- Immunoregulatory Cells for Chronic Inflammatory Disease

Expected Milestones & Goals:

- ✔ Currently evaluating co-development and/or out-licensing opportunities for **VY-UC**, **VY-OZ**, **VY-M** and **VY-X** with new partnerships expected to be announced in 2022
- ✔ World-class research team with highly-proficient expertise in T cell and NK cell immunology, cell engineering and gene editing is developing new classes of allogeneic NK-cell based cancer immunotherapy with goal to submit INDs in 2023
- ✔ Proof-of-Concept *in vivo* evaluations have shown **VY-X** to demonstrate significant anti-tumor activity in multiple myeloma models with goal to report IND-enabling study results in 2022/23
- ✔ Forming key alliances, exemplified by partnerships with Avectas to evaluate **VY-M** in non-viral systems to accelerate cell manufacturing and reduce costs and with NextGenNK to advance next-generation NK cell-based immunotherapies

Board of Directors:



Evren Alici, M.D., Ph.D.: CEO & Chairman of the Board
Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Hans-Gustaf Ljunggren, M.D., Ph.D.: Chief Medical Officer
Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Douglas W. Calder: President
Board Member, NextGenNK; Board Member, BioFlorida; Member, Society for Natural Immunity; former executive & officer roles at the Vaccine & Gene Therapy Institute, Accentia Biopharmaceuticals, Biovest and Viragen



Michael J. Keller, J.D.: Exec VP, Intellectual Property
CEO, Keller Life Science Law; former roles include Chief Patent Counsel for IVAX, partner at leading IP law firms, and technology transfer roles at the National Cancer Institute (NCI)



Samuel Duffey, Esq.: Exec VP, General Counsel
General Counsel for MyMD Pharmaceuticals; former roles include CEO & President of Biovest International, a pioneer in the development of neoantigen cancer vaccines, and Senior Attorney at SEC

Scientific Advisory Board:

Gunnar Kaufmann, Ph.D.: Chief Scientific Officer at Oncternal Therapeutics, Inc., and Adjunct Assistant Professor in the Dept of Chemistry and Immunology and Microbial Science at The Scripps Research Institute

Bruce L. Levine, Ph.D.: Barbara and Edward Netter Professor in Cancer Gene Therapy & Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

Karl-Johan Malmberg, M.D., Ph.D.: Professor, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital

James Mulé, Ph.D.: Associate Center Director for Translational Science, McGillicuddy Endowed Chair in Melanoma Research/Treatment, and Scientific Director of Cell-based Therapies at Moffitt Cancer Center

Adel Nada, M.D., M.S., MFPM: Founding CEO of GentiBio, Inc., and former Chief Medical Officer, Casebia Therapeutics, a joint venture launched by Bayer and CRISPR Therapeutics

For more information, please contact:

Douglas W. Calder, President
Phone: 772-418-6302
dcalder@Vycellix.com
www.Vycellix.com

Moffitt Cancer Center, Fowler Campus
4105 East Fowler Ave.
Tampa, FL 33617 USA

Disclaimer: Certain statements contained in this Fact Sheet and/or in other documents of Vycellix, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties.

